Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

Journal of Immunological Methods

Volumn 373, Issue 1-2, 2011, Pages 67-78

  Repp, Roland ^a   Kellner, Christian ^a   Muskulus, Anja ^a   Staudinger, Matthias ^a   Mohseni Nodehi, Sahar ^a   Glorius, Pia ^a   Akramiene, Dalia ^e   Dechant, Michael ^a   Fey, Georg H ^b   van Berkel, Patrick H C ^d   van de Winkel, Jan G J ^c,d   Parren, Paul W H I ^d   Valerius, Thomas ^a   Gramatzki, Martin ^a   Peipp, Matthias ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d GENMAB   (Netherlands)

^e KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

ADCC; Antibody glycosylation; CD16; Fc engineering; NK cells; ScFv

Indexed keywords

CD16 ANTIGEN; CD16A ANTIGEN; CD20 ANTIGEN; CD7 ANTIGEN; FC PROTEIN; HUMAN IMMUNOGLOBULIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; FUCOSYLATION; GLYCOSYLATION; HLA SYSTEM; HUMAN; HUMAN CELL; MUTAGENESIS; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD7; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; FUCOSE; GLYCOPROTEINS; HLA-D ANTIGENS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; KILLER CELLS, NATURAL; MUTAGENESIS; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, FC; RECEPTORS, IGG; SINGLE-CHAIN ANTIBODIES;

EID: 80054839351     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.08.003     Document Type: Article

References (49)

1. Beerli R.R., Bauer M., Buser R.B., Gwerder M., Muntwiler S., Maurer P., Saudan P., Bachmann M.F. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14336-14341.
2. Bosques C.J., Collins B.E., Meador J.W., Sarvaiya H., Murphy J.L., Dellorusso G., Bulik D.A., Hsu I.H., Washburn N., Sipsey S.F., Myette J.R., Raman R., Shriver Z., Sasisekharan R., Venkataraman G. Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat. Biotechnol. 2010, 28:1153-1156.
3. Bruenke J., Fischer B., Barbin K., Schreiter K., Wachter Y., Mahr K., Titgemeyer F., Niederweis M., Peipp M., Zunino S.J., Repp R., Valerius T., Fey G.H. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br. J. Haematol. 2004, 125:167-179.
4. Camani C., Gavin O., Bertossa C., Samatani E., Kruithof E.K. Studies on the effect of fucosylated and non-fucosylated finger/growth-factor constructs on the clearance of tissue-type plasminogen activator mediated by the low-density-lipoprotein-receptor-related protein. Eur. J. Biochem. 1998, 251:804-811.
5. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6:343-357.
6. Chao G., Lau W.L., Hackel B.J., Sazinsky S.L., Lippow S.M., Wittrup K.D. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 2006, 1:755-768.
7. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
8. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., Martens A., Verbeek J.S., Parren P.W., van de Winkel J.G., Leusen J.H. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010, 70(8):3209-3217.
9. Desjarlais J.R., Lazar G.A., Zhukovsky E.A., Chu S.Y. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov. Today 2007, 12:898-910.
10. Ferrara C., Stuart F., Sondermann P., Brunker P., Umana P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 2006, 281:5032-5036.
11. Ferrara C., Grau S., Jager C., Sondermann P., Brunker P., Waldhauer I., Hennig M., Ruf A., Rufer A.C., Stihle M., Umana P., Benz J. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc{gamma}RIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(31):12669-12674.
12. Hayden-Ledbetter M.S., Cerveny C.G., Espling E., Brady W.A., Grosmaire L.S., Tan P., Bader R., Slater S., Nilsson C.A., Barone D.S., Simon A., Bradley C., Thompson P.A., Wahl A.F., Ledbetter J.A. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res. 2009, 15:2739-2746.
13. Hodoniczky J., Zheng Y.Z., James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 21:1644-1652.
14. Houde D., Peng Y., Berkowitz S.A., Engen J.R. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol. Cell. Proteomics 2010, 9:1716-1728.
15. Iida S., Misaka H., Inoue M., Shibata M., Nakano R., Yamane-Ohnuki N., Wakitani M., Yano K., Shitara K., Satoh M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin. Cancer Res. 2006, 12:2879-2887.
16. Imai-Nishiya H., Mori K., Inoue M., Wakitani M., Iida S., Shitara K., Satoh M. Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 2007, 7:84.
17. Jefferis R. Glycosylation of natural and recombinant antibody molecules. Adv. Exp. Med. Biol. 2005, 564:143-148.
18. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
19. Jefferis R., Lund J., Goodall M. Recognition sites on human IgG for Fc gamma receptors: the role of glycosylation. Immunol. Lett. 1995, 44:111-117.
20. Jefferis R., Lund J., Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 1998, 163:59-76.
21. Kanda Y., Yamane-Ohnuki N., Sakai N., Yamano K., Nakano R., Inoue M., Misaka H., Iida S., Wakitani M., Konno Y., Yano K., Shitara K., Hosoi S., Satoh M. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 2006, 94:680-688.
22. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., Dahiyat B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4005-4010.
23. Lund J., Takahashi N., Pound J.D., Goodall M., Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 1996, 157:4963-4969.
24. Masuda K., Kubota T., Kaneko E., Iida S., Wakitani M., Kobayashi-Natsume Y., Kubota A., Shitara K., Nakamura K. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 2007, 44:3122-3131.
25. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., Neri T.M., Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
26. Natsume A., Wakitani M., Yamane-Ohnuki N., Shoji-Hosaka E., Niwa R., Uchida K., Satoh M., Shitara K. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J. Immunol. Methods 2005, 306:93-103.
27. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
28. Nimmerjahn F., Ravetch J.V. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 2007, 19:239-245.
29. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
30. Oganesyan V., Gao C., Shirinian L., Wu H., Dall'Acqua W.F. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr. D Biol. Crystallogr. 2008, 64:700-704.
31. Patnaik S.K., Stanley P. Lectin-resistant CHO glycosylation mutants. Methods Enzymol. 2006, 416:159-182.
32. Peipp M., Simon N., Loichinger A., Baum W., Mahr K., Zunino S.J., Fey G.H. An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells. J. Immunol. Methods 2001, 251:161-176.
33. Peipp M., Kupers H., Saul D., Schlierf B., Greil J., Zunino S.J., Gramatzki M., Fey G.H. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002, 62:2848-2855.
34. Peipp M., Lammerts van Bueren J.J., Schneider-Merck T., Bleeker W.W., Dechant M., Beyer T., Repp R., van Berkel P.H., Vink T., van de Winkel J.G., Parren P.W., Valerius T. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 2008, 112:2390-2399.
35. Peipp M., Schneider-Merck T., Dechant M., Beyer T., van Bueren J.J., Bleeker W.K., Parren P.W., van de Winkel J.G., Valerius T. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J. Immunol. 2008, 180:4338-4345.
36. Preithner S., Elm S., Lippold S., Locher M., Wolf A., da Silva A.J., Baeuerle P.A., Prang N.S. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulinG. Mol. Immunol. 2006, 43:1183-1193.
37. Presta L.G., Shields R.L., Namenuk A.K., Hong K., Meng Y.G. Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. 2002, 30:487-490.
38. Ripka J., Adamany A., Stanley P. Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Arch. Biochem. Biophys. 1986, 249:533-545.
39. Rondot S., Koch J., Breitling F., Dubel S. A helper phage to improve single-chain antibody presentation in phage display. Nat. Biotechnol. 2001, 19:75-78.
40. Scallon B.J., Tam S.H., McCarthy S.G., Cai A.N., Raju T.S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 2007, 44:1524-1534.
41. Schaffitzel C., Hanes J., Jermutus L., Pluckthun A. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods 1999, 231:119-135.
42. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591-6604.
43. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 2002, 277:26733-26740.
44. Siemiatkoski J., Lyubarskaya Y., Houde D., Tep S., Mhatre R. A comparison of three techniques for quantitative carbohydrate analysis used in characterization of therapeutic antibodies. Carbohydr. Res. 2006, 341:410-419.
45. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., Huang L., Vijh S., Johnson S., Bonvini E., Koenig S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007, 67:8882-8890.
46. Thie H., Meyer T., Schirrmann T., Hust M., Dubel S. Phage display derived therapeutic antibodies. Curr. Pharm. Biotechnol. 2008, 9:439-446.
47. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17:176-180.
48. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
49. Zhao X., Lapalombella R., Joshi T., Cheney C., Gowda A., Hayden-Ledbetter M.S., Baum P.R., Lin T.S., Jarjoura D., Lehman A., Kussewitt D., Lee R.J., Caligiuri M.A., Tridandapani S., Muthusamy N., Byrd J.C. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007, 110:2569-2577.